这些结果和Takada有关uPA抑制物在肿瘤生物学中作用的结论引起其他研究者的兴趣。如果PAI-1和PAI-2抑制uPA，那么为何PAI-1似乎能增加肿瘤的生长和转移并使患者的预后较差为何同样抑制uPA而且在肿瘤组织10倍于PAI-1的PAI-2却抑制肿瘤发展Takada小组最近的研究表明PAI-2可诱导肿瘤细胞凋亡。uPA-R∶uPA∶PAI-2复合物可能给肿瘤细胞一个死亡信号。果真如此，则PAI-2可为人们提供抑制肿瘤的好疗法。
1 Beherendt N, Stephens RW. The urokinasee receptor. Fibrinolysis Proteolysis, 1998, 12: 191-204.
2 Petesen LC, Lund LR, Nielsen LS,et al. One-chain urokinase-type plasminogen activator from human sarcoma cells is a protenzyme with little or no intrinsic activity. J Biol Chem, 1988,263: 11189-11195.
3 Felez J. Plasminogen binding to cell surface. Fibrinolysis Proteolysis, 1998, 12:183-189.
4 Behrendt N, Dano K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett, 1996, 393:31-36.
5 Elllis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of prourokinase. J Biol Chem, 1996,271:14779-14784.
6 Schmitt M, Hartbeck N,Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target therapy. Thromb Haemost, 1997, 78:285-296.
7 Basher H, Urano T, Fukuta K, et al. Plasminogen activatiors and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int, 1994, 54:4-8.
8 Nakamura N, Konno H, Tanaka T, et al. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res,1992, 65: 709-712.
9 Nagayama M, Sato A, Hayakawa H, et al. Plasminogen activators and their inhibitor in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 1994, 73: 1398-1405.
10 Morita S, Sato A，Hayakawa H, et al. Cancer cells overexpress mRNA of urokinase-type plasminogen activator. Its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. Int J Cancer, 1998, 78: 286-292.
11 Wagner SN, Atkinson MJ, Thaner S, et al. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol, 1995, 147:183-192.
12 Yamamoto M, Sawaya R, Mohanama S, et al. Expression and cellul ar localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytmas in vivo. Cancer Res, 1994,54:3329-3332.
13 Evans D, Lin P. Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg, 1995, 61:692-696.
14 Foekens JA, Bussecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res, 1995, 55: 1423-1427.
